# LimFlow

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/limflow

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.limflow.com/
- Total disclosed funding: $106M
- Latest round: Series D (Mar 31, 2022)
- Investors on record: 6

## About

Based in Paris, France, LimFlow SA specializes in innovative medical solutions focused on treating vascular diseases, particularly through their proprietary catheter-based system designed for end-stage peripheral artery disease (PAD).LimFlow SA, established in 2012 in Paris, France, focuses on developing medical technologies for vascular treatment. The company was founded by Martin Rothman, who has a history of entrepreneurial endeavors in the medical field. Inari Medical, Inc. recently agreed to acquire LimFlow for an upfront payment of USD 250.000 mn, with the deal finalized on November 1, 2023, allowing for additional payments upon achieving certain milestones. The firm has successfully completed a total of 10 deals since its inception.LimFlow specializes in innovative medical solutions aimed at addressing critical needs in the treatment of vascular diseases. Their core product offering is centered around a proprietary catheter-based system designed to restore blood flow in patients with end-stage peripheral artery disease (PAD), specifically targeting individuals who have not responded to conventional therapies. This system facilitates a minimally invasive procedure that enables healthcare providers to establish a new pathway for blood flow without the need for major surgery. LimFlow's products serve hospitals and healthcare facilities, primarily focusing on markets in North America and Europe, where the demand for advanced treatment options for PAD is growing. The end users are typically patients suffering from this debilitating condition, as well as the medical professionals who administer care.In 2023, LimFlow reported revenue of USD 410,495, with an EBITDA of USD -38,122,160.9. The company's revenue model is structured around the sale of its catheter systems and associated medical devices to healthcare providers, including hospitals and specialty clinics. Transactions are based on a direct-to-business sales model, where healthcare facilities purchase devices based on patient needs and treatment protocols. Each transaction involves the sale of individual catheter systems and may also include training and support services for medical staff.Following the acquisition by Inari Medical, Inc., LimFlow aims to leverage its innovative technology to expand patient access to life-saving treatments for chronic limb-threatening ischemia. The recent funding will be utilized to enhance product offerings and expand into new markets, particularly targeting regions in North America and Europe. The strategic acquisition supports Inari Medical’s goal of addressing critical unmet medical needs, thus establishing a broader geographical presence and enhancing service capabilities in the vascular treatment sector.

## Funding rounds

- Series D, Mar 31, 2022, $39M — Sofinnova Partners, Longitude Capital, Bpifrance Investissement, Inari Medical, Inc., Balestier Investments, Soleus Capital
- Series C, Mar 15, 2022, $2.2M — Sofinnova Partners, Bpifrance Investissement, Balestier Investments
- Series C, Aug 18, 2021, $4.7M — Sofinnova Partners, Bpifrance Investissement, Balestier Investments
- Series C, Dec 12, 2019, $17M — Sofinnova Partners, Bpifrance Investissement, Balestier Investments
- Series C, Jun 1, 2018, $21M — Sofinnova Partners, Bpifrance Investissement, Balestier Investments
- Series B, Dec 18, 2017, $4.7M — Bpifrance Investissement, Balestier Investments
- Series A, Aug 15, 2014, $17M — Bpifrance Investissement, Balestier Investments

## Investors

- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B, Series C, Series D
- Balestier Investments — Series A, Series B, Series C, Series D
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series C, Series D
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series D
- Inari Medical, Inc. — Series D
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series D